🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Triple-Negative Breast Cancer

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies NCT07064018Phase 1, Phase 21 site📍 Orange University of California, Irvine · Tests: Spedox-6, Pegfilgrastim, Filgrastim A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer NCT06246968Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Pembrolizumab, Cryoablation, Histotripsy Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer NCT04159142Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine A Multicenter Cancer Biospecimen Collection Study NCT04510129n/a1 site📍 San Francisco Cofactor Genomics, Inc. · Tests: OncoPrism™ assay Capecitabine in Low Risk Triple Negative Breast Cancer NCT06787339Phase 21 site📍 Shanghai Fudan University · Tests: Capecitabine DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer NCT05504707Phase 11 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: HER2 - primed Dendritic cells, HER3 - primed Dendritic cells Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT NCT05314114NA1 site📍 Beijing Peking University · Tests: No axillary surgery EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase NCT06894173n/a29 sites📍 Aviano📍 Ancona📍 Avellino Fondazione Policlinico Universitario Agostino Gemelli IRCCS A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs NCT06908928Phase 17 sites📍 Duarte📍 La Jolla📍 Aurora Mabwell (Shanghai) Bioscience Co., Ltd. · Tests: bulumtatug fuvedotin, bulumtatug fuvedotin A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer NCT06732323Phase 31 site📍 Beijing Qilu Pharmaceutical Co., Ltd. · Tests: ESG401, Investigator's Choice Chemotherapy Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251Phase 1, Phase 213 sites📍 New Haven📍 Sarasota📍 Tampa Avenzo Therapeutics, Inc. · Tests: AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042Phase 1, Phase 26 sites📍 Scottsdale📍 Denver📍 New Haven Simcha IL-18, Inc. · Tests: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) NCT05633654Phase 3376 sites📍 Birmingham📍 Huntsville📍 Glendale Gilead Sciences · Tests: Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer NCT05541367n/a1 site📍 Wuhan Tongji Hospital fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases NCT06328465NA1 site📍 Milan European Institute of Oncology · Tests: Diffusion whole body MRI Tier Palliative Care For Patients With Advanced Heart Failure or Cancer NCT07391956NA5 sites📍 Astoria📍 New York📍 New York Icahn School of Medicine at Mount Sinai · Tests: Tier-Palliative Care, Community Health Worker LAG3 Expression in Triple Negative Breast Cancer NCT06259162NA1 site📍 Seoul Samsung Medical Center · Tests: LAG-3 expression / immune checkpoint protein expression Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) NCT07011654Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Sacituzumab govitecan, Naxitamab SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) NCT06401005Phase 21 site📍 Wuhan Hubei Cancer Hospital · Tests: Cadonilimab (AK104) 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871Phase 1, Phase 25 sites📍 Dothan📍 Grand Rapids📍 Omaha Radiopharm Theranostics, Ltd · Tests: 177Lu-BetaBart, BetaBart + unlabeled BetaBart 99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer NCT06104085NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: 99mTc-MY6349 SPECT/CT scan 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT) NCT06349512NA6 sites📍 Antony📍 Paris📍 Paris Institut Curie · Tests: 68Ga-FAPI-46 PET/CT imaging Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients NCT04159818Phase 21 site📍 Amsterdam The Netherlands Cancer Institute · Tests: Nivolumab, Cisplatin, Low dose doxorubicin Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC NCT05464082Phase 21 site📍 Salt Lake City University of Utah · Tests: Functional Precision Oncology Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer NCT06954480Phase 22 sites📍 London📍 London Queen Mary University of London · Tests: Datopotamab Deruxtecan (Dato-DXd), Durvalumab Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer NCT06635980Phase 21 site📍 Scottsdale Mayo Clinic · Tests: Biopsy of Breast, Biospecimen Collection, Breast Surgery, Chemotherapy, Computed Tomography Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer NCT05491083Phase 1, Phase 21 site📍 Singapore National University Hospital, Singapore · Tests: Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers NCT07545122Phase 16 sites📍 Wahroonga📍 Westmead📍 Gold Coast Context Therapeutics Inc. · Tests: CT-202 A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer NCT06508216Phase 1, Phase 21 site📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: Dato-DXd, Durvalumab A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) NCT06926868Phase 2, Phase 3295 sites📍 Hot Springs📍 Cerritos📍 Cerritos Bristol-Myers Squibb · Tests: Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy